Drugs Information Online
Drugs and diseases reference index

Drugs and diseases reference index

Drugs A-Z List

Diseases & Conditions A-Z List

Herbs & Supplements

Medical Dictionary

Full Article

Popular Drugs

Popular Diseases & Conditions

Drugs reference index «Amlodipine»



Pronunciation: (am-LOE-di-peen)Class: Calcium channel blocking agent

Trade Names:Norvasc- Tablets 2.5 mg- Tablets 5 mg- Tablets 10 mg


Inhibits movement of calcium ions across cell membrane in systemic and coronary vascular smooth muscle.



T max is 6 to 12 h. Bioavailability is 64% to 90%. Steady state is reached after 7 to 8 days of consecutive daily dosing.


About 93% is protein bound.


About 90% is converted to inactive metabolites in the liver.


10% of the parent compound and 60% of the metabolites are excreted in the urine. Elimination is biphasic. Half-life is about 30 to 50 h.

Special Populations

Renal Function Impairment

Pharmacokinetics not significantly influenced.

Hepatic Function Impairment

Cl is decreased and AUC may increase about 40% to 60%.


Cl is decreased and AUC may increase about 40% to 60%.

Moderate to severe heart failure

Cl is decreased and AUC may increase about 40% to 60%.

Indications and Usage

Treatment of hypertension; treatment of chronic stable angina; or vasospastic (Prinzmetal or variant) angina; reduction of the risk of hospitalization caused by angina; reduction of the risk of coronary revascularization procedure in patients with recently documented coronary artery disease (CAD).


Standard considerations.

Dosage and Administration


PO Initial dose is 5 mg daily (max, 10 mg daily). 2.5 mg daily when adding amlodipine to other antihypertensive therapy.

Children 6 to 17 years of age

PO 2.5 to 5 mg once daily.


PO 5 to 10 mg once daily.

Chronic stable or vasospastic anginaAdults

PO 5 to 10 mg once daily.


PO Start with 5 mg once daily.

Hepatic ImpairmentHypertension

PO Initially 2.5 mg every day.

Chronic stable or vasospastic angina

PO Start with 5 mg once daily.


PO Initially 2.5 mg every day.

General Advice

  • Adjust dose as needed; titration should proceed over 7 to 14 days.
  • Administer without regard to meals.


Store at 59° to 86°F.

Drug Interactions

Azole antifungals (eg, ketoconazole)

Concurrent use may increase the plasma concentrations of amlodipine.

Protease inhibitors (eg, ritonavir)

Pharmacologic effects of amlodipine may be increased.

Vasopressin receptor antagonists (conivaptan)

Plasma concentrations of amlodipine may be increased.

Laboratory Test Interactions

None well documented.

Adverse Reactions


Flushing, palpitations (5%).


Headache (7%); fatigue (5%); dizziness (3%); somnolence (2%).


Nausea (3%); abdominal pain (2%).


Hepatic enzyme elevations, jaundice (postmaketing).


Edema (15%); gynecomastia (postmarketing).



Category C .




Safety and efficacy not established in children younger than 6 yr of age.


May require lower initial dose.

Hepatic Function

Use with caution in patients with severe hepatic impairment.


Use with caution in patients with severe aortic stenosis or CHF.

Increased angina/MI

May occur when starting therapy or at the time of dosage increase.


Abrupt withdrawal may cause increased frequency and duration of chest pain. Gradually taper dose if amlodipine is to be discontinued.



Hypotension, peripheral vasodilation, reflex tachycardia.

Patient Information

  • Teach patient how to monitor pulse before taking medication. Tell patient not to take medication if pulse is less than 50 bpm and to contact health care provider.
  • Explain to patient how to monitor BP daily.
  • Instruct patient not to stop taking this medication suddenly because doing so can cause chest pain and MI.
  • Inform patient that frequent follow-up appointments with health care provider are important to adjust medication dosage.
  • Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to take with or without food.
  • Advise breast-feeding woman not to breast-feed.
  • Advise patient that drug may cause drowsiness, and to use caution while driving or performing other tasks requiring mental alertness.

Copyright © 2009 Wolters Kluwer Health.

  • Amlodipine MedFacts Consumer Leaflet (Wolters Kluwer)
  • Amlodipine Prescribing Information (FDA)
  • amlodipine Advanced Consumer (Micromedex) - Includes Dosage Information
  • Norvasc Prescribing Information (FDA)
  • Norvasc Consumer Overview
  • Norvasc Detailed Consumer Information (PDR)

See Also...

Comment «Amlodipine»